Search

Displaying results 5561 - 5570 of 7897 in total
  1. Drug

    BNT111

    go.drugbank.com/drugs/DB18177
    Investigational

    BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.

  2. Drug

    GW-468816

    go.drugbank.com/drugs/DB15099
    Experimental

    GW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).

  3. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  4. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    IGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  5. Drug

    RS5441

    go.drugbank.com/drugs/DB33178
    Experimental

    RS5441, also known as ET-02, is a small molecule topical medication investigated for male pattern baldness and age-related alopecia.[L57508, L57509]

  6. Drug

    Plixorafenib

    go.drugbank.com/drugs/DB16038
    Investigational

    PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).

  7. Drug

    Filaminast

    go.drugbank.com/drugs/DB02660
    Experimental

    Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

  8. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

  9. Drug

    Propentofylline

    go.drugbank.com/drugs/DB06479
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.